JP7110096B2 - レトロウイルス産生のための一時的トランスフェクション法 - Google Patents

レトロウイルス産生のための一時的トランスフェクション法 Download PDF

Info

Publication number
JP7110096B2
JP7110096B2 JP2018526787A JP2018526787A JP7110096B2 JP 7110096 B2 JP7110096 B2 JP 7110096B2 JP 2018526787 A JP2018526787 A JP 2018526787A JP 2018526787 A JP2018526787 A JP 2018526787A JP 7110096 B2 JP7110096 B2 JP 7110096B2
Authority
JP
Japan
Prior art keywords
nucleic acid
retroviral
vector
acid vector
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018526787A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019500030A (ja
JP2019500030A5 (OSRAM
Inventor
サビン、ジョンソン
セレステ、パラント
エイリーニ、バンバ
コンラッド、ビンク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1520764.0A external-priority patent/GB201520764D0/en
Priority claimed from GBGB1609354.4A external-priority patent/GB201609354D0/en
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of JP2019500030A publication Critical patent/JP2019500030A/ja
Publication of JP2019500030A5 publication Critical patent/JP2019500030A5/ja
Application granted granted Critical
Publication of JP7110096B2 publication Critical patent/JP7110096B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/50—Vectors for producing vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2018526787A 2015-11-24 2016-11-21 レトロウイルス産生のための一時的トランスフェクション法 Active JP7110096B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1520764.0 2015-11-24
GBGB1520764.0A GB201520764D0 (en) 2015-11-24 2015-11-24 Transient transfection method for retroviral production
GBGB1609354.4A GB201609354D0 (en) 2016-05-26 2016-05-26 Transient transfection method for retroviral production
GB1609354.4 2016-05-26
PCT/EP2016/078334 WO2017089307A1 (en) 2015-11-24 2016-11-21 Transient transfection method for retroviral production

Publications (3)

Publication Number Publication Date
JP2019500030A JP2019500030A (ja) 2019-01-10
JP2019500030A5 JP2019500030A5 (OSRAM) 2020-01-09
JP7110096B2 true JP7110096B2 (ja) 2022-08-01

Family

ID=57348703

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018526787A Active JP7110096B2 (ja) 2015-11-24 2016-11-21 レトロウイルス産生のための一時的トランスフェクション法

Country Status (15)

Country Link
US (2) US10450574B2 (OSRAM)
EP (1) EP3380605A1 (OSRAM)
JP (1) JP7110096B2 (OSRAM)
KR (1) KR102067352B1 (OSRAM)
CN (1) CN108291211A (OSRAM)
AU (1) AU2016359838B2 (OSRAM)
BR (1) BR112018010639A2 (OSRAM)
CA (1) CA3006285A1 (OSRAM)
DE (1) DE102016122317A1 (OSRAM)
FR (1) FR3044017B1 (OSRAM)
IL (1) IL259223B (OSRAM)
IT (1) IT201600117287A1 (OSRAM)
RU (1) RU2749717C2 (OSRAM)
SA (1) SA518391585B1 (OSRAM)
WO (1) WO2017089307A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3294756T3 (da) * 2015-05-15 2021-02-22 Flash Therapeutics Retroviral partikel, omfattende mindst to forskellige indkapslede, ikke-virale RNA'er
BR112018010635A2 (pt) * 2015-11-24 2018-11-27 Glaxosmithkline Ip Dev Ltd linhagens celulares estáveis para a produção retroviral
GB201706121D0 (en) * 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Stable cell lines for retroviral production
GB201715052D0 (en) 2017-09-19 2017-11-01 Oxford Genetics Ltd Vectors
FI3633040T3 (fi) 2017-12-22 2023-08-03 Oxford Biomedica Ltd Retrovirusvektori
GB201816919D0 (en) * 2018-10-17 2018-11-28 Glaxosmithkline Ip Dev Ltd Adeno-associated viral vector producer cell lines
CN110684804B (zh) * 2019-10-15 2023-04-18 上海本导基因技术有限公司 递送外源rnp的慢病毒载体及其制备方法
GB202004371D0 (en) 2020-03-26 2020-05-13 Glaxosmithkline Ip Dev Ltd CAR constructs
GB202005096D0 (en) 2020-04-07 2020-05-20 Glaxosmithkline Modified vectors for production of retrovirus
KR20220166825A (ko) * 2020-04-10 2022-12-19 사우스웨스트 리서치 인스티튜트 바이러스 벡터 생산을 위한 3차원 생물 반응기
EP4308605A1 (en) 2021-03-19 2024-01-24 GlaxoSmithKline Intellectual Property Development Limited Chimeric antigen receptors targeting claudin-3 and methods for treating cancer
CN113373266B (zh) * 2021-06-22 2022-07-01 内蒙古农业大学 一种用于检测绵羊肺腺瘤病毒的荧光rpa引物、试剂盒和检测方法
WO2024218341A1 (en) 2023-04-19 2024-10-24 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for car-t and car-nk cells
WO2024218345A1 (en) 2023-04-21 2024-10-24 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005512573A (ja) 2001-10-30 2005-05-12 バイレクシス コーポレイション 調節された核酸発現系
US20060057553A1 (en) 2000-05-30 2006-03-16 Estuardo Aguilar-Cordova Chimeric viral vectors for gene therapy
JP2010517554A (ja) 2007-02-12 2010-05-27 アーク・セラピューティックス・リミテッド レンチウイルスベクターの作製
JP2015165810A (ja) 2007-03-23 2015-09-24 ウィスコンシン アラムニ リサーチ ファンデーション 体細胞の再プログラム化
JP2015529466A (ja) 2012-09-14 2015-10-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 鎌状赤血球症の幹細胞遺伝子治療のためのレンチウイルスベクター

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
WO1995003400A1 (en) 1993-07-23 1995-02-02 Johns Hopkins University School Of Medicine Recombinationally targeted cloning in yeast artificial chromosomes
ES2253754T3 (es) * 1995-06-27 2006-06-01 Bavarian Nordic A/S Celulas encapsuladas que producen particulas viricas.
WO1997030169A1 (en) 1996-02-13 1997-08-21 Fred Hutchinson Cancer Research Center 10a1 retroviral packaging cells and uses thereof
FR2751223B1 (fr) * 1996-07-19 1998-12-04 Rhone Merieux Formule de vaccin polynucleotidique felin
US6277621B1 (en) 1998-02-26 2001-08-21 Medigene, Inc. Artificial chromosome constructs containing foreign nucleic acid sequences
ATE384795T1 (de) 1998-12-31 2008-02-15 Novartis Vaccines & Diagnostic Modifizierte hiv env polypeptide
AU4364700A (en) 1999-04-22 2000-11-10 General Hospital Corporation, The Triple hybrid amplicon vector systems to generate retroviral packaging lines
US6677155B1 (en) 1999-04-22 2004-01-13 The General Hospital Corporation Triple hybrid amplicon vector systems to generate retroviral packaging lines
WO2000066758A1 (en) 1999-04-29 2000-11-09 Aarhus University Expression of heterologous genes from an ires translational cassette in retroviral vectors
AU5597200A (en) 1999-06-07 2000-12-28 Cell Genesys, Inc. Hybrid yeast-bacteria cloning system and uses thereof
WO2001027304A2 (en) 1999-10-12 2001-04-19 Institut Pasteur Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
AU2001292711A1 (en) 2000-09-18 2002-03-26 Genetic Therapy, Inc. Stress resistant retroviruses
US6586251B2 (en) * 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7214515B2 (en) 2001-01-05 2007-05-08 The General Hospital Corporation Viral delivery system for infectious transfer of large genomic DNA inserts
DE10111433A1 (de) 2001-03-09 2002-09-19 Bundesrepublik Deutschland Let Replikationskompetente molekulare Klone von porcinem endogenem Retrovirus der Klasse A und Klasse B,abgeleitet von Schweine- und humanen Zellen
WO2002097059A2 (en) 2001-05-30 2002-12-05 Chromos Molecular Systems, Inc. Chromosome-based platforms
EP2348119B1 (en) 2002-02-01 2017-04-26 Oxford BioMedica (UK) Limited Multicistronic lentiviral vector
ATE471382T1 (de) 2002-04-10 2010-07-15 Us Gov Health & Human Serv Vac-bac-shuttlevektor-system
US7300658B2 (en) * 2002-11-25 2007-11-27 Bavarian Nordic A/S Recombinant poxvirus comprising at least two compox ATI promoters
WO2005106002A2 (en) * 2004-04-28 2005-11-10 The Trustees Of The University Of Pennsylvania Polyvalent viral vectors and a system for production thereof
US20080226677A1 (en) 2004-05-06 2008-09-18 Yasuko Mori Recombinant virus vector for gene transfer into lymphoid cells
EP1652932A1 (en) 2004-11-02 2006-05-03 GBF Gesellschaft für Biotechnologische Forschung mbH Method for the generation of virus producing cell lines and cell lines
EP1817422A2 (en) 2004-11-24 2007-08-15 Nanovector Limited Viral vectors
EP1829963A4 (en) * 2004-11-24 2009-01-28 Anaeropharma Science Inc NEW SHUTTLE VECTOR
EP2062246A4 (en) 2006-08-18 2010-09-29 Univ North Carolina VACCINES AGAINST CHIMARICAL VIRUSES
WO2009146150A2 (en) 2008-04-04 2009-12-03 University Of Miami Viral recombineering and uses thereof
BR112013005120A2 (pt) 2010-09-02 2021-04-20 Molmed S.P.A produção semiestável de vetores lentivirais
US9273324B2 (en) 2010-12-05 2016-03-01 Andrew S. Belmont Recombinant gene expression
WO2012170431A2 (en) 2011-06-06 2012-12-13 Bluebird Bio, Inc. Improved geneswitch systems
GB201202516D0 (en) 2012-02-13 2012-03-28 Ucl Business Plc Materials and methods relating to packaging cell lines
US10590433B2 (en) * 2014-03-14 2020-03-17 University Of Washington Genomic insulator elements and uses thereof
GB2538321A (en) 2015-05-15 2016-11-16 Glaxosmithkline Ip Dev Ltd Artificial chromosome for retroviral production
GB2538324A (en) 2015-05-15 2016-11-16 Glaxosmithkline Ip Dev Ltd Packaging cell line for retroviral production
KR102058113B1 (ko) * 2015-11-23 2019-12-23 주식회사 엘지화학 접착력이 개선된 리튬 이차전지용 전극 및 이의 제조방법
BR112018010635A2 (pt) 2015-11-24 2018-11-27 Glaxosmithkline Ip Dev Ltd linhagens celulares estáveis para a produção retroviral

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060057553A1 (en) 2000-05-30 2006-03-16 Estuardo Aguilar-Cordova Chimeric viral vectors for gene therapy
JP2005512573A (ja) 2001-10-30 2005-05-12 バイレクシス コーポレイション 調節された核酸発現系
JP2010517554A (ja) 2007-02-12 2010-05-27 アーク・セラピューティックス・リミテッド レンチウイルスベクターの作製
JP2015165810A (ja) 2007-03-23 2015-09-24 ウィスコンシン アラムニ リサーチ ファンデーション 体細胞の再プログラム化
JP2015529466A (ja) 2012-09-14 2015-10-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 鎌状赤血球症の幹細胞遺伝子治療のためのレンチウイルスベクター

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Teru Kanda，Production of high-titer Epstein-Barr virus recombinants derived from Akata cells by using a bacterial artificial chromosome system，J Virol.，2004年，78(13)，p.7004-7015
川口 寧，3. BACシステム : 大腸菌遺伝学とウイルス学が融合した新しいヘルペスウイルスの遺伝子改変法，ウイルス，2004年，54巻2号，P.255-264

Also Published As

Publication number Publication date
RU2018118964A3 (OSRAM) 2020-04-02
BR112018010639A2 (pt) 2019-01-22
IT201600117287A1 (it) 2018-05-21
RU2018118964A (ru) 2019-12-26
CN108291211A (zh) 2018-07-17
FR3044017A1 (fr) 2017-05-26
US20200063144A1 (en) 2020-02-27
IL259223A (en) 2018-07-31
AU2016359838A1 (en) 2018-05-24
JP2019500030A (ja) 2019-01-10
EP3380605A1 (en) 2018-10-03
AU2016359838B2 (en) 2020-08-06
US20170145427A1 (en) 2017-05-25
IL259223B (en) 2022-05-01
DE102016122317A1 (de) 2017-05-24
KR20180073624A (ko) 2018-07-02
SA518391585B1 (ar) 2020-10-26
CA3006285A1 (en) 2017-06-01
WO2017089307A1 (en) 2017-06-01
RU2749717C2 (ru) 2021-06-16
KR102067352B1 (ko) 2020-01-16
US10450574B2 (en) 2019-10-22
FR3044017B1 (fr) 2019-05-03

Similar Documents

Publication Publication Date Title
JP7110096B2 (ja) レトロウイルス産生のための一時的トランスフェクション法
AU2016360763B2 (en) Stable cell lines for retroviral production
JP6878620B2 (ja) レトロウイルス産生のための安定な細胞株
GB2538321A (en) Artificial chromosome for retroviral production
GB2538324A (en) Packaging cell line for retroviral production
US20250122528A1 (en) Lentiviral vector
GB2544891A (en) Transient transfection method for retroviral production

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220325

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220624

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220720

R150 Certificate of patent or registration of utility model

Ref document number: 7110096

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150